Sonoma Pharmaceuticals (SNOA) Retained Earnings (2011 - 2025)

Sonoma Pharmaceuticals' Retained Earnings history runs 15 years deep, the most recent figure standing at -$200.4 million for Q4 2025.

• In Q4 2025, Retained Earnings fell 1.71% year-over-year to -$200.4 million; the TTM figure through Dec 2025 stood at -$200.4 million (down 1.71% YoY), while the FY2025 annual figure was -$197.8 million, down 1.78% from the prior year.
• Retained Earnings was -$200.4 million for Q4 2025 at Sonoma Pharmaceuticals, down from -$3.4 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$2.8 million in Q4 2023 to a low of -$200.4 million in Q4 2025.
• Historically, Retained Earnings has averaged -$125.2 million across 5 years, with a median of -$180.9 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Retained Earnings soared 98.32% in 2023, then sank 6879.45% in 2024.
• A 5-year view of Retained Earnings shows it stood at -$181.4 million in 2021, then surged by 97.7% to -$4.2 million in 2022, then soared by 32.4% to -$2.8 million in 2023, then tumbled by 6879.45% to -$197.0 million in 2024, then dropped by 1.71% to -$200.4 million in 2025.
• The last three Retained Earnings figures came in at -$200.4 million (Q4 2025), -$3.4 million (Q3 2025), and -$199.0 million (Q2 2025), per Business Quant data.